Skip to main content
. 2019 Nov 7;19:939. doi: 10.1186/s12879-019-4588-9

Table 1.

Patient characteristics and incidence (episode/1000 admission)

Candida species
Total C. albicans C. glabrata C. tropicalis C. krusei C. parapsilosis Othersh
(n = 243)
100.0%
(n = 110)
45.3%
(n = 73)
30.0%
(n = 37)
15.2%
(n = 12)
4.9%
(n = 5)
2.1%
(n = 6)
2.5%
Patient characteristics
 Age (years)
  16–49 70 (28.8) 32 (45.7) 23 (32.8) 8 (11.4) 3 (4.3) 2 (2.9) 2 (2.9)
  50–65 84 (34.6) 24 (28.6) 35 (41.6) 15 (17.9) 6 (7.1) 2 (2.4) 2 (2.4)
   > 65 89 (36.6) 54 (60.7) 15 (16.9) 14 (15.7) 3 (3.4) 1 (1.1) 2 (2.2)
 Gender
  Male 139 (57.2) 60 (43.2) 41 (29.5) 28 (20.1) 4 (2.9) 4 (2.9) 2 (1.4)
  Female 10 4 (42.8) 50 (48.1) 32 (30.8) 9 (8.7) 8 (7.7) 1 (0.9) 4 (3.8)
 Underlying comorbidities (n, %)
  Gastrointestinal perforation 48 (19.6) 24 (50.0) 10 (20.8) 8 (16.7) 5 (10.4) 0 (0) 1 (2.1)
  Respiratory dysfunctiona 51 (21.0) 25 (49.0) 16 (31.4) 9 (17.6) 0 (0) 0 (0) 1 (2.0)
  Pulmonary infection 81 (33.3) 43 (53.1) 20 (24.7) 14 (17.3) 1 (1.2) 1 (1.2) 2 (2.5)
  Cardiovascular disease 78 (32.1) 41 (52.6) 20 (25.6) 10 (12.8) 5 (6.4) 0 (0) 2 (2.6)
  Neurological diseases 58 (23.9) 35 (60.4) 10 (17.2) 9 (15.5) 2 (3.5) 1 (1.7) 1 (1.7)
  Gastrointestinal pathologyb 63 (25.9) 32 (50.8) 18 (28.6) 7 (11.1) 5 (7.9) 1 (1.6) 0 (0)
  Chronic/acute liver disease 45 (18.5) 22 (48.9) 9 (0.2) 10 (22.2) 3 (6.7) 1 (2.2) 0 (0)
  Chronic/acute renal failurec 90 (37.0) 48 (53.3) 23 (25.6) 15 (16.7) 2 (2.2) 0 (0) 2 (2.2)
  Solid tumour 22 (9.1) 11 (50.0) 2 (9.1) 7 (31.8) 2 (9.1) 0 (0) 0 (0)
  Haematological malignancy 6 (2.5) 3 (50.0) 1 (16.7) 1 (16.7) 0 (0) 0 (0) 1 (16.6)
  Severe autoimmune diseases 11 (4.5) 7 (63.6) 0 (0) 3 (27.3) 1 (9.1) 0 (0) 0 (0)
  Diabetes mellitus 93 (38.3) 57 (61.3) 19 (20.4) 11 (11.8) 6 (6.5) 0 (0) 0 (0)
  Burns 6 (2.5) 2 (33.3) 1 (16.7) 1 (16.7) 0 (0) 2 (33.3) 0 (0)
  HIV/AIDS 13 (5.3) 2 (15.4) 10 (76.9) 0 (0) 0 (0) 0 (0) 1 (7.7)
  Severe trauma 15 (6.2) 6 (40.0) 3 (20.0) 4 (26.6) 1 (6.7) 1 (6.7) 0 (0)
 Risk factors (n, %)
  Presence of CVCd 118 (48.6) 59 (50.0) 23 (19.5) 24 (20.3) 8 (6.8) 2 (1.7) 2 (1.7)
  Mechanical ventilation 82 (33.7) 41 (50.0) 19 (23.2) 15 (18.3) 5 (6.1) 1 (1.2) 1 (1.2)
  Receipt of corticosteroidse 70 (28.8) 43 (61.4) 12 (17.1) 14 (20.0) 1 (1.4) 0 (0) 0 (0)
  Total parenteral nutrition 119 (49.0) 62 (52.1) 29 (24.4) 19 (16.0) 7 (5.9) 1 (0.8) 1 (0.8)
  Chemotherapy 11 (4.5) 4 (36.4) 1 (9.1) 5 (45.4) 1 (9.1) 0 (0) 0 (0)
  Abdominal surgeryf 69 (28.4) 26 (37.7) 27 (39.1) 10 (14.5) 4 (5.8) 0 (0) 2 (2.9)
  Intensive care in adults 42 (17.3) 21 (50.0) 9 (21.4) 8 (19.0) 2 (4.8) 1 (2.4) 1 (2.4)
  Neutropeniag 7 (2.9) 4 (57.1) 0 (0) 1 (14.3) 2 (28.6) 0 (0) 0 (0)
  Concomitant bacterial infections 81 (33.3) 46 (56.8) 13 (16.0) 18 (22.3) 2 (2.5) 1 (1.2) 1 (1.2)
  Septic shock 46 (18.9) 16 (34.8) 19 (41.4) 7 (15.2) 2 (4.3) 0 (0) 2 (4.3)
  Dialysis 25 (10.3) 9 (36.0) 13 (52.0) 2 (8.0) 0 (0) 0 (0) 1 (4.0)
 Previous antibiotics therapy 215 (88.5) 103 (47.9) 60 (27.9) 35 (16.3) 12 (5.6) 1 (0.5) 4 (1.8)
  Treatment with antifungal agents 83 (34.2) 44 (53.0) 20 (24.1) 14 (16.9) 3 (3.6) 0 (0) 2 (2.4)
 Incidence (episodes/1000 admissions)
  2013 0.16 0.05 0.06 0.03 0.01 0 0.01
  2014 0.31 0.16 0.07 0.06 0.01 0 0.01
  2015 0.43 0.18 0.13 0.06 0.04 0.02 0
  2016 0.52 0.28 0.13 0.05 0.03 0 0.03
  2017 0.66 0.25 0.23 0.12 0.02 0.03 0.01

aIncludes the following diseases: chronic obstructive pulmonary disease and acute respiratory distress syndrome

bIncludes the following diseases: cholecystitis, pancreatitis, and peritonitis

cChronic/Acute renal failure is the permanent or sudden and often temporary loss of kidney function with N waste retention and hypourocrinia

dCVC central venous catheter

ea dose equivalent to the prednisone dosage of 0.3 mg/kg/day for at least 14 days

fincluding: gastrointestinal perforations, severe acute pancreatitis and complex ventral hernia

gNeutropenia is the absolute neutrophil count, that is, < 500 cells/μl

hOthers include C. guilliermondii (3), C. haemulonii (2) and C. pseudotropicalis (1)